15 results
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and the establishment and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like
424B5
yai1ueb5
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
hxa1hh3n1 u9it
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
30g8q56o5ntmhffq3i
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
dg4x4wgn31zxnv88
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
S-1/A
0amrs1s mq
1 Jul 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next